2010 financials
Novartis posts strong Q3 results
October 21, 2010Sales and Marketing 2010 financials, Novartis, Novartis quarterly results, Q3, pharma sales
Novartis has posted double digit growth for the third quarter following a strong showing by a number of recently launched …
Roche revenue depressed by plummeting Tamiflu sales
October 15, 2010Sales and Marketing 2010 financials, Q3, Roche
Roche suffered a 3% drop in group revenue in the third quarter as sales of its Tamiflu plummeted by 90 …
Generic competition hits Boehringer sales
August 9, 2010Sales and Marketing 2010 financials, Boehringer, Q2
Boehringer Ingelheim’s sales fell 5% in the first half of 2010, depressed by generic competition and then further dragged down …
Victoza lifts Novo Nordisk
August 9, 2010Sales and Marketing 2010 financials, Novo Nordisk, Q2
Novo Nordisk has posted a set of healthy results following strong sales from its insulin range and newly launched diabetes …
Wyeth acquisition boosts Pfizer results
August 4, 2010Sales and Marketing 2010 financials, Pfizer, Q2
Pfizer’s second quarter results received a huge boost from the company’s multi-billion dollar acquisition of Wyeth last October. Sales of …
New products help lift UCB
August 3, 2010Sales and Marketing 2010 financials, Q2, UCB
UCB’s newer products showed impressive growth in the first six months of this year, helping keep the Belgium-based biopharma firm’s …
Merck merger costs halve profits
August 2, 2010Sales and Marketing 2010 financials, Merck & Co, Q2
Shares in Merck & Co fell as costs relating to the merger with Schering-Plough put a huge dent in second …
FDA recommends Brilinta
July 30, 2010Sales and Marketing 2010 financials, AstraZeneca, Brillinta, Q2
FDA advisors have voted in favour of AstraZeneca’s antiplatelet drug Brilinta, which is currently seeking a licence for the reduction …
Sanofi’s blockbusters take a hit
July 29, 2010Sales and Marketing 2010 financials, Genzyme, Q2, Sanofi-Aventis
Generic pressures, European pricing pressures and the impact of the US health reforms combined to dent Sanofi-Aventis’s growth in the …
Lonza boosts profit despite contract manufacturing downturn
July 23, 2010Manufacturing and Production 2010 financials, Lonza, Q2
Switzerland’s Lonza posted a healthy increase in profits in the first half of 2010, topping analysts’ expectations, although sales dipped …
Roche sees slow sales amid market pressures
July 22, 2010Sales and Marketing 2010 financials, Q2, Roche
Roche has posted average first half year results with pharma sales that showed only low single digit growth. They showed …
Abbott boosted by Solvay integration
July 22, 2010Sales and Marketing 2010 financials, Abbott, Q2, Solvay
Abbott has posted a set of strong sales for the second quarter, buoyed by the integration of Solvay Pharmaceuticals and …
Manufacturing woes hit Genzyme results
July 22, 20102010 financials, Genzyme, Q2
Genzyme has posted a decrease in sales for the second quarter as its manufacturing woes continue. The US-based biopharma company …
Legal costs dent GlaxoSmithKline’s Q2
July 22, 2010Medical Communications, Sales and Marketing 2010 financials, GlaxoSmithKline, Q2
GSK has reported a loss for its second quarter due to litigation costs related to Avandia and other problems. In …
J&J post modest second quarter increase
July 21, 2010Sales and Marketing 2010 financials, J&J, JJ, Q2
Johnson & Johnson has seen a modest increase in sales for the second quarter, buoyed primarily by international sales and …
